ÂÜÀòÂÒÂ×

Over her career, Alana McNulty has led or played a key role in transactions with an aggregate value greater than $2 billion, including private and public financings, mergers and acquisitions, corporate partnerships, and debt financings. She is currently Chief Business Officer of eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). She also served as Chief Financial Officer for eFFECTOR for more than eight years. Prior to eFFECTOR, Ms. McNulty served as Chief Financial Officer of a number of biopharmaceutical companies, including Lumena Pharmaceuticals, Inc. (acquired by Shire plc), Excaliard Pharmaceuticals, Inc. (acquired by Pfizer Inc.), BrainCells Inc., and Elitra Pharmaceuticals, Inc. Prior to that, Ms. McNulty was Head of Corporate Development and a General Manager of a business unit at Advanced Tissue Sciences, Inc. Ms. McNulty received a B.A. in biology with high honors from UC Santa Barbara, where she graduated Phi Beta Kappa, and an MBA from the Anderson School of Business at UCLA.